England Expects Biosimilar Savings Of Up To Half A Billion
With a tender and reference prices for adalimumab now in place, NHS England has raised its forecast for annual savings through biosimilar competition to half a billion pounds.
With a tender and reference prices for adalimumab now in place, NHS England has raised its forecast for annual savings through biosimilar competition to half a billion pounds.